4-(二乙氨基)丁腈 | 5336-75-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(二乙氨基)丁腈
• 英文名称: 4-(diethylamino)butyronitrile
• 英文别名: 4-diethylaminobutyronitrile；4-diethylamino-butyronitrile；4-Diaethylamino-butyronitril；4-Diaethylamino-buttersaeure-nitril；4-(diethylamino)-butanenitrile；4-Diethylamino-buttersaeurenitril；4-(Diethylamino)butanenitrile
• CAS: 5336-75-4
• 化学式: C₈H₁₆N₂
• mdl: MFCD00019893
• 分子量: 140.228
• InChiKey: NUVVGLXJJPTXRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  89-90 °C (9 mmHg)
• 密度：
  0.84
• 稳定性/保质期：
  在常温常压下稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2926909090
• 储存条件：
  密封储存，应存放在阴凉、干燥的库房中。

SDS

Name:	4-(Diethylamino)butanenitrile 97% Material Safety Data Sheet
Synonym:	4-Diethylaminobutyronitril
CAS:	5336-75-4

Section 1 - Chemical Product MSDS Name:4-(Diethylamino)butanenitrile 97% Material Safety Data Sheet
Synonym:4-Diethylaminobutyronitril

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5336-75-4	4-(Diethylamino)butanenitrile	97	226-259-1

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Water may be ineffective. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5336-75-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear brown
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 89.0 - 90.0 deg C @ 9.00mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: .8400g/cm3
Molecular Formula: C8H16N2
Molecular Weight: 140.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
No information found..
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5336-75-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Diethylamino)butanenitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 5336-75-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5336-75-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5336-75-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(二乙氨基)丁腈 在 rhodium on alumina 氢气 作用下， 以 甲醇 为溶剂， 生成 bis-(4-diethylamino-butyl)-amine
  参考文献：
  名称：

  肿瘤抑制剂。70.与索拉帕米汀有关的N-酰基三胺之间的结构-细胞毒性关系。

  摘要：

  DOI：

  10.1021/jm00271a017
• 作为产物：
  描述：

  (Diaethylaminoaethyl)-cyanessigsaeureaethylester 在 盐酸 作用下， 生成 4-(二乙氨基)丁腈
  参考文献：
  名称：

  Some Dialkylaminoalkylamines

  摘要：

  DOI：

  10.1021/ja01225a507

文献信息

• Bromoform reaction of tertiary amines with N,N-dibromosulfonamides or NBS/sulfonamides
  作者：Jie Chen、Yu-Ping Guo、Ming-Hui Sun、Guo-Tao Fan、Ling Zhou

  DOI：10.1039/c4cc05578k

  日期：——

  A new bromoform reaction of tertiary amines with N,N-dibromosulfonamides or NBS/sulfonamides has been developed. A series of amidines were prepared with moderate to good yields via a Csp(3)-Csp(3) bond cleavage.

  已经开发出叔胺与N，N-二溴磺酰胺或NBS /磺酰胺的新的溴仿反应。通过Csp（3）-Csp（3）键裂解制备了一系列中等至良好收率的am。
• Regioselective Covalent Modification of Hemoglobin in Search of Antisickling Agents
  作者：Soobong Park、Brittany L. Hayes、Fatima Marankan、Debbie C. Mulhearn、Linda Wanna、Andrew D. Mesecar、Bernard D. Santarsiero、Michael E. Johnson、Duane L. Venton

  DOI：10.1021/jm020361k

  日期：2003.3.1

  the resulting increase in solubility of the modified hemoglobin. Depending on the attached R-group, the isothiocyanates were found to react either with the Cysbeta93 or the N-terminal amine of the alpha-chain. One of the most effective compounds in the series, 2-(N,N-dimethylamino)ethyl isothiocyanate, selectively reacts with the thiol of Cysbeta93 which, in conjunction with the cationic group, was seen

  尽管镰状血红蛋白产生镰状细胞疾病的分子缺陷已经知道了数十年，但仍然没有有效的药物治疗作用于血红蛋白本身。在这项工作中，检查了一系列不同取代的异硫氰酸盐（R-NCS）与血红蛋白的区域选择性反应，试图改变镰刀型血红蛋白的溶解性。电喷雾质谱，分子建模，X射线晶体学和常规蛋白质化学用于研究这种区域选择性以及由此产生的修饰血红蛋白溶解度的增加。取决于所连接的R基团，发现异硫氰酸酯与Cysbeta93或α链的N端胺反应。该系列中最有效的化合物之一，2-（N，N-二甲基氨基）乙基异硫氰酸酯，与Cysbeta93的巯基发生选择性反应，后者与阳离子基团一起干扰了局部的血红蛋白结构。这种改性的HbS在完全脱氧状态下显示出约30％的溶解度增加，同时氧亲和力也显着增加。该化合物和相关的类似物似乎很容易穿过红细胞膜。讨论了这些结构变化与抑制胶凝的关系。增强HbS氧亲和力并直接抑制脱氧HbS聚合的双重活性，以及​​易
• Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06541505B1

  公开（公告）日：2003-04-01

  This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

  这项发明涉及一种化合物，其化学式为I，该化合物是(aminoiminomethyl或aminomethyl)benzoheteroaryl化合物，可通过将该化合物与含有凝血因子Xa的组合物结合来抑制凝血因子Xa的活性。本发明还涉及含有化合物I的组合物、其制备方法以及它们的用途，如用于抑制凝血酶的形成或用于治疗患有与生理上有害的凝血酶过量相关的疾病状态的患者。
• Novel benzothiazepine and bensothiepine compounds
  申请人：Sasahara Takehiko

  公开号：US20070190041A1

  公开（公告）日：2007-08-16

  A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided. A benzothiazepine or benzothiepine compound represented by the following formula (1A) having a thioamide bond and a quaternary ammonium substitutent:

  提供了一种药物，可用作治疗和预防高脂血症的治疗剂和预防剂，以及一种药物，可用作治疗和预防与胆汁淤积有关的肝脏疾病，特别是原发性胆汁性肝硬化和原发性硬化性胆管炎的治疗剂和预防剂，以及一种药物，可用作治疗和预防肥胖症、脂肪肝和脂肪性肝炎的治疗剂和预防剂。化合物的苯并噻吩或苯并噻环代表如下式（1A），具有硫酰胺键和季铵取代基：
• Novel quaternary ammonium compounds
  申请人：Sasahara Takehiko

  公开号：US20070203115A1

  公开（公告）日：2007-08-30

  A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):

  一种抑制回肠胆汁酸转运蛋白活性的方法，包括向该受试者施用一种由式（1）所代表的化合物的有效量：